MELBOURNE, Australia and PRINCETON, N.J., July 09, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel ...
JS207, Junshi Biosciences’ independently developed recombinant humanized anti-PD-1/VEGF bispecific antibody, has demonstrated promising anti-tumor activity and a manageable safety profile in both ...
PD-L1 expression and its prognostic value in metastatic papillary renal cell carcinoma: Results from a GETUG multicenter retrospective cohort. This is an ASCO Meeting Abstract from the 2024 ASCO ...
Direct anti-VEGF angiogenic agents were a strong risk factor for high-grade hypertension, and multikinase inhibitors for high-grade proteinuria. Vascular endothelial growth factor signaling pathway ...
Anti-VEGF therapy improves outcomes in retinal diseases by targeting neovascularization and macular edema, crucial in conditions like AMD and diabetic retinopathy. Optical coherence tomography is ...
Add Yahoo as a preferred source to see more of our stories on Google. This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma ...
VEGFNP/SDFNP delivery reduced pulmonary arterial pressure, vascular resistance, and vessel thickening, nearly preventing right ventricular hypertrophy in PAH rats. The treatment increased eNOS ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results